1. Preparation and Evaluation of Novel Sugar Dendritic Gd-DTPA Complexes for MRI Contrast Agents and Phospha Sugars for Anti-Tumour Agents
- Author
-
Valluru Krishna Reddy, Kengo Aoshima, Nobuhisa Ozaki, Nao Kamikage, Mayumi Yamaoka, Gang Yu, Satoru Ito, Sophie Laurent, Mitsuji Yamashita, Manabu Yamada, Keita Kiyofuji, Michio Fujie, Harumi Sakahara, Satoki Nakamura, Luce Vander Elst, Junko Yamashita, Hisao Takayanagi, Kazuhide Asai, Kenji Tsunekawa, Yasuo Takehara, Takuya Suyama, Carmen Burtea, Reiko Makita, Keisuke Ogawa, Takashi Aoki, Robert N. Muller, and Masaki Sugiyama
- Subjects
MRI contrast agent ,General Engineering ,Epoxide ,In vitro ,chemistry.chemical_compound ,medicine.anatomical_structure ,Imatinib mesylate ,chemistry ,Biochemistry ,In vivo ,medicine ,Sugar ,Blood vessel ,K562 cells - Abstract
Novel Sugar Dendritic Gd(III)-DTPA complexes for MRI Contrast Agents (CAs) were prepared and evaluated by in vitro and in vivo methods. The sugar dendritic MRI contrast agents had a good blood vessel pool character and drew blood vessels and liver cancers remarkably clearer and longer time enough than the clinically being used Gd(III)-DTPA complex (Magnevist). Phospha sugar derivatives or phosphorus heterocyclic derivatives provided by functional groups such as epoxide, bromide, etc., were prepared and evaluated by the MTT in vitro method. These phospha sugar derivatives showed excellent anti-proliferative effects of leukemia cell lines, e.g., K562 and U937, as well as solid cancer cells in fashions of (i) higher activity, (ii) wider spectra, and (iii) higher selectivity and specificity than Imatinib mesylate (Gleevec), which is one of the most frequently used chemotherapeutical molecular targeting anti-tumour agent.
- Published
- 2011
- Full Text
- View/download PDF